-
12.02.2024 | CARB-X to partner with Clinton Health Access Initiative on gonorrhea-focused interventions
CIDRAP | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) and the Clinton Health Access Initiative (CHAI) announced today that they are teaming up to explore interventions to slow the spread of gonorrhea in low- and middle-income countries (LMIC).
-
11.26.2024 | CARB-X and CHAI partner to sharpen AMR response, tackle gonorrhea in low- and middle-income countries
CLINTON HEALTH ACCESS INITIATIVE | CARB-X and CHAI are partnering to evaluate the clinical needs and address market barriers for diagnostic, preventative, and therapeutic interventions targeting gonorrhea infections in low- and middle-income countries.
-
11.26.2024 | Fighting back against antimicrobial resistance: Partnerships and innovations
HINDUSTAN TIMES | The global threat of antimicrobial resistance (AMR) is one of the most pressing public health challenges of our time. In India, this silent pandemic threatens to undermine decades of medical progress as previously treatable bacterial infections increasingly defy conventional antibiotic interventions.
-
11.19.2024 | The superbug fight needs a better business model
GLOBAL HEALTH NOW | Antimicrobial resistance is already a leading cause of death worldwide—with a global burden of disease greater than HIV, malaria, and tuberculosis combined. Yet as AMR deaths spiral and the need grows for drugs that work against deadly infections, the pipeline for new antibiotics is drying up, not ramping up.
-
11.19.2024 | Strengthening early-stage AMR innovation: A conversation with Dr. Erin Duffy, Chief of Research & Development at CARB-X
WUXI APPTEC | As the global threat of antimicrobial resistance (AMR) intensifies, CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) plays a pivotal role in tackling this crisis by focusing exclusively on the earliest stages of product development.
-
11.18.2024 | What recommendations have been made since the O’Neill report?
MARKS & CLERK | Since the publication of Jim O'Neill's 2016 report on AMR, several recommendations have seen partial implementation, while others still require attention.
-
11.16.2024 | UKZN Professor wins top accolade
INDEPENDENT ONLINE | Professor Sabiha Essack, the South African Research Chair (SARChI) in Antibiotic Resistance and One Health, Professor in Pharmaceutical Sciences at the University of KwaZulu-Natal (UKZN) and Honorary Professor of Pharmacy at the University of Jordan, has been awarded the Christiana Figueres Policy to Practice Award.
-
11.15.2024 | Using more and better data to solve the puzzle of antimicrobial resistance
IQVIA | Discussions in New York in the context of the UN General Assembly High-Level Meeting on Antimicrobial Resistance (AMR) showed the interest and determination of many stakeholders in finding solutions to this issue, stressing the need for progress in areas such as sustainable funding, diagnostics, research and development, prevention tools, clinical practice, national guidelines and policies, partnership platforms, and healthcare system infrastructure.
-
11.15.2024 | Preventing antimicrobial resistance: Key steps to take
NEWS MEDICAL | Microorganisms that develop resistance to antimicrobial drugs are referred to as "superbugs" . These microbes have been detected in more than 204 countries across the world.
-
11.14.2024 | A pathogen’s plight: The international lethal pandemic of antibiotic-resistant bacteria
GLIMPSE FROM THE GLOBE | Pathogenic bacteria that cause infectious diseases have posed some of the greatest threats to human survivorship. These infamous bacterial diseases include tuberculosis, anthrax and pneumonia.
-
11.14.2024 | As world’s Health Ministers meet in Jeddah: Calls for strong AMR science panel with authority to ‘challenge’ sponsors
HEALTH POLICY WATCH | With plans underway for a new “Independent Panel” on Antimicrobial Resistance, endorsed at September’s UN High-Level AMR Meeting, the new body must become a strong scientific authority.
-
11.13.2024 | New initiative by the Italian Embassy in Washington on biotechnology with the Milken Institute and leading researchers and industry experts
ITALIAN EMBASSY IN WASHINGTON | Italy’s focus on biotechnology—as reflected in the development of a national strategy—demonstrates our aspiration to play a leading role internationally in developing solutions to major global health challenges.
-
10.31.2024 | A world without antibiotics
FOREIGN POLICY | Antibiotics are the foundation of modern medicine, but with each passing year, they are becoming less effective. Bacteria and other microorganisms are quickly evolving to thwart the effects of antimicrobial drugs, making infections more dangerous, and medical treatments riskier.
-
10.31.2024 | NTI | bio, CEPI convene inaugural Bio Funders Forum to champion responsible innovation and research practices
NUCLEAR THREAT INITIATIVE | As emerging technologies transform life science research and broaden access to advanced capabilities to engineer living systems, responsible innovation hinges on funding decisions that carefully weigh potential benefits against inherent risks.
-
10.29.2024 | From intention to action: The promise of innovation to address AMR
GLOBAL AMR R&D HUB | For decades, antimicrobials have revolutionised modern medicine, greatly improving health outcomes. However, their effectiveness is now compromised from the very present and growing threat of antimicrobial resistance (AMR).
-
10.28.2024 | On the front lines of the superbug war, new treatments can’t arrive soon enough
PHARMAVOICE | As antimicrobial resistance rises, researchers are running out of time to fight each new wave of superbugs. And the funding isn’t enough.
-
10.22.2024 | Italian government gives $21 million to BU-led effort to develop new antibiotics, vaccines, diagnostics
THE BRINK | A Boston University–led nonprofit that’s taking on the growing threat of antibiotic-resistant bacteria has just received a significant injection of new funding—from the Italian government.
-
10.21.2024 | Italy to provide funding for CARB-X
CIDRAP | The government of Italy has announced a commitment of $21 million over 3 years to support the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
-
10.16.2024 | Report highlights progress in efforts to incentivize antibiotic R&D
CIDRAP | A new report calls attention to some of the progress that's been made over the past year to incentivize antibiotic development while emphasizing how much more work there is to be done.
-
10.15.2024 | Super batteri, la nuova pandemia è già qui: parte la caccia ai nuovi antibiotici
IL SOLE 24 ORE | Già oggi provoca 11mila morti l'anno soltanto in Italia. Secondo l'Oms diventerà la prima causa di morte nel 2050.
-
10.11.2024 | Documents of the Health Ministers’ Meeting in Ancona
G7 ITALIA | The G7 Health Ministers, gathered in Ancona from 9 to 11 October, adopted today a Joint Declaration, which Minister Orazio Schillaci described as “ambitious and which includes and summarises the common stances on all the issues addressed during these months”.
-
10.11.2024 | G7 Italia, il comunicato conclusivo della Riunione dei Ministri della Salute
MINISTERO DELLA SALUTE | “È una dichiarazione politica ambiziosa, che include e riassume le posizioni comuni su tutte le tematiche affrontate durante questi mesi”.
-
10.11.2024 | Il piano italiano contro l’antibiotico resistenza: “Nel 2050 sarà la prima causa di morte”
LA STAMPA | Un po' per l'uso smodato che se ne fa, in parte perche negli ospedali non si presta ancora l'attenzione necessaria a prevenire le infezioni e in misura non e inferiore per il fatto che l'industria ha smesso di fare ricerca sui nuovi antibiotic.
-
10.11.2024 | G7 Salute: 21 mln di dollari per nuovi antibiotici, la mossa dell’Italia
FORTUNE ITALIA | Non prendono alla leggera la minaccia di un’Apocalisse antibiotica i ministri riuniti ad Ancona per il G7 Salute.
-
10.11.2024 | La resistenza agli antibiotici è la vera pandemia da affrontare
AVVENIRE | Il ministro Schillaci ha annunciato il piano per affrontare quella che ha definito «un'emergenza globale». il governo ha in programma assunzioni di medici e infermieri per i prossimi tre anni
-
09.30.2024 | Funding the future: Sustainable financing models to help the fight against antimicrobial resistance
FORBES | The growing problem of antimicrobial resistance, or AMR, has been called a “silent pandemic”, a “slow-motion tsunami”, and one of the “top 10 global health threats to humanity in the 21st century”.
-
09.26.2024 | Key players in the fight against antibiotic-resistant bacteria
FINTECH ZOOM | The rise of antibiotic-resistant bacteria poses a significant threat to global health, challenging the effectiveness of traditional treatments for bacterial infections. From common urinary tract infections to life-threatening conditions like cystic fibrosis, the need for innovative solutions has an impact on various medical fields.
-
09.25.2024 | It’s time to sound the alarm on superbugs
PEW CHARITABLE TRUSTS | The United Nations General Assembly’s first high-level meeting on antimicrobial resistance (AMR) in 2016 was a pivotal moment, highlighting the scope and urgency of this public health crisis.
-
09.16.2024 | Drug-resistant infections are on the rise – so why aren’t we getting any new antibiotics?
THE GUARDIAN | World leaders will meet in New York this month to discuss growing antimicrobial resistance as researchers warn the development of replacement drugs is stalling.
-
09.03.2024 | More countries are addressing AMR, but many reluctant to commit to specific cut to animal antibiotic use
HEALTH POLICY WATCH | While more countries are concerned about antimicrobial resistance (AMR) than a decade ago, many are reluctant to commit to a specific target to reduce the overuse of animal antibiotics as they negotiate a political declaration ahead of the United Nations high-level meeting on AMR.
-
09.02.2024 | Explained: the history of progress in tackling antimicrobial resistance
WELLCOME | This century has seen greater political interest in antimicrobial resistance and increased efforts to monitor, understand and treat drug-resistant infections. Is enough being done to tackle a growing global health crisis?
-
08.21.2024 | What happens when the last AMR researcher turns off the lights in the lab?
INFECTIOUS DISEASE SPECIAL EDITION | Much of modern medicine is possible because of antibiotics. Orthopedic surgeries, caesarean deliveries, and heart and kidney transplants are made safer by antibiotics.
-
07.25.2024 | House Budget Committee examines budgetary effects of antimicrobial resistance and the broken antibiotic development pipeline
HOUSE BUDGET COMMITTEE | CARB-X Executive Director Kevin Outterson joined other industry experts at a House Budget Committe bipartisan roundtable entitled “Threats to Modern Medicine: Examining the Budgetary Effects of Antimicrobial Resistance and the Broken Antibiotic Development Pipeline.”
-
04.17.2024 | As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene
PHARMAVOICE | AMR is a growing threat, but with little financial incentive to pick up the torch, government and nonprofit collaborations are keeping the R&D flames burning.
-
03.08.2024 | Professor Kevin Outterson speaks on antimicrobial resistance
TUFTS DAILY | Kevin Outterson, a professor at Boston University, bridges economics, health equity and scientific research in his discussion about how to combat antimicrobial resistance.
-
03.06.2024 | Non-profits take over from Big Pharma in new drugs trials
JUTA MEDICAL BRIEF | Effective, affordable antimicrobial drugs are desperately needed around the world, and last November, a clinical trial offered a glimmer of hope, when an oral antibiotic, called zoliflodacin, was shown to be effective against the bacterium that causes gonorrhoea.
-
03.06.2024 | CARB-X funds 100th project—a milestone for BU-based nonprofit leading antimicrobial-resistance fightback
THE BRINK | Global partnership led by BU law professor has now given $452.6 million in funding to support promising new antibiotics, vaccines, and rapid diagnostics—and is ready to support more projects.
-
03.05.2024 | With new award, CARB-X hits the 100-project mark in battling antibiotic resistance
CIDRAP | CARB-X today announced funding for its 100th project addressing antimicrobial resistance (AMR).
-
02.28.2024 | Can non-profits beat antibiotic resistance and soaring drug costs?
NATURE | Last November, a clinical trial offered a glimmer of hope in the often gloomy fight against antimicrobial resistance. An oral antibiotic, called zoliflodacin, was shown to be effective against the bacterium that causes the sexually transmitted disease gonorrhoea.
-
02.15.2024 | Could a single synthetic molecule outsmart a variety of drug-resistant bacteria?
LOS ANGELES TIMES | An estimated 2.8 million people in the U.S. contract infections each year from bacteria resistant to antibiotics, according to the U.S. Centers for Disease Control. More than 35,000 of them die.
Toggle navigation